首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 125 毫秒
1.
根据GenBank中的I型鸭肝炎病毒全基因序列设计了扩增I型鸭肝炎病毒VP1、3D基因的引物, 用该特异性表达引物从I型鸭肝炎病毒cDNA模板中扩增得到目的基因VP1、3D, 用相同的限制性内切酶酶切目的基因和表达载体pET32a后构建重组表达载体, 转化宿主BL21(DE3), 用不同浓度的IPTG诱导VP1、3D基因的表达, 收集菌液进行SDS-PAGE电泳, Western-blotting分析蛋白免疫原性。结果表明, VP1、3D在大肠杆菌中表达量较高, 表达产物的分子量约为48 kD、68 kD, 并能被兔抗DHV-1血清所识别。I型鸭肝炎病毒VP1、3D蛋白在大肠杆菌中表达产物具有免疫原性。  相似文献   

2.
从实验室冻存的含A型口蹄疫病毒的细胞中提取FMDV总RNA,通过RT-PCR获得cDNA.并根据FMDV全基因组序列设计了一对针对VP0基因的引物,通过PCR扩增得到目的基因VP0并亚克隆入pMD18-T载体.将鉴定出的阳性质粒和表达载体pET32a用BamH Ⅰ和HindⅢ双酶切回收后连接获得阳性重组质粒pET32-VP0.用IPTG诱导重组质粒表达目的蛋白VP0并用SDS-PAGE进行检测.表达产物用镍亲和树脂进行了纯化.结果证明,口蹄疫病毒VP0蛋白在大肠杆菌中获得了高效表达且表达产物得到了纯化,为实验室进一步的研究提供了重要的材料.  相似文献   

3.
猪肥胖基因在大肠杆菌中的高效融合表达   总被引:2,自引:2,他引:0  
采用PCR方法扩增猪肥胖基因编码原成熟蛋白cDNA序列,并在5′端加上BamHⅠ位点,3′端加上EoRⅠ位点,将5′端密码子CCC转变为大肠杆菌常见密码子CCG,扩增得到459bp的片段,克隆于融合表达载体p GEX-2TBamHⅠ和EcoRⅠ位点,酶切、测序正确,经0.1mmol/LIPTG诱导表达出一条约42kD的融合蛋白,其中26kD为pGEX-2T中带有的谷胱苷肽转移酶,16kD是猪肥胖基因表达产物瘦蛋白。利用非融合表达产品制备抗血清,检测融合表达的重组蛋白,Western-blot为阳性。  相似文献   

4.
鸡传染性贫血病毒VP2基因的表达及其免疫活性分析   总被引:2,自引:0,他引:2  
利用特异性引物从组织病料中提取的鸡传染性贫血病毒核酸经PCR扩增得到VP2基因,BamHⅠ和SalⅠ双酶切处理,纯化后,克隆至BamHⅠ和SalⅠ双酶切处理的表达载体pET-28a中,构建了原核表达质粒pET-28-VP2。将pET-28-VP2转化至感受态E.coliBL21(DE3)中,经IPTG诱导和SDS-PAGE分析,可见约31kDa的目的蛋白以可溶性形式表达于上清中。Western blot分析发现,表达产物与鸡传染性贫血的阳性血清发生特异性反应。纯化蛋白免疫小鼠后制得的多抗可以与全病毒发生反应,证明其具有免疫原性,为进一步研究VP2蛋白的功能及开展CIAV疫苗及诊断试剂的研制奠定了基础。  相似文献   

5.
根据类球红菌(Rhodobacter sphaeroides2.4.1)自诱导物合成酶基因cerⅠ的序列,设计并合成了1对特异性引物,在引物的5′和3′分别加入含有HindⅢ和XhoⅠ限制性酶切位点的序列,以类球红细菌Rhodobactersphaeroides基因组为模板扩增了cerⅠ基因序列。将PCR产物与pMD18-T载体连接,转化大肠杆菌DH5α。鉴定成功获得目的片段,经HindⅢ和XhoⅠ双酶切后与载体pET-28a(+)连接,构建原核表达质粒pET-28a(+)-cerⅠ,并将其转化宿主菌BL21(DE3),用IPTG诱导其表达。SDS-PAGE分析表明,重组载体pET-28a(+)-cerⅠ可成功地在大肠杆菌中表达cerⅠ蛋白。  相似文献   

6.
【目的】研究鸭甲肝病毒(Duck hepatitis A virus,DHAV)1型VP3和3型VP1串联基因在大肠杆菌中的表达,并以纯化的重组蛋白为抗原建立鸭病毒性肝炎抗体检测的间接ELISA方法。【方法】设计2对特异性引物,提取鸭甲肝病毒1型(DHAV-1)和3型(DHAV-3)的RNA,分别RT-PCR扩增得到714bp的DHAV-1VP3和720bp的DHAV-3 VP1基因,并克隆至p MD18-T载体中,然后依次将DHAV-1 VP3和DHAV-3 VP1定向插入p ET-32a(+)表达载体,获得重组表达载体p ET-1VP3-3VP1,进行IPTG(Isopropyl-beta-D-1-thiogalactopyranoside)诱导表达分析,以纯化的重组蛋白为抗原建立间接ELISA方法并应用于临床。【结果】经IPTG诱导表达,在大肠杆菌中可稳定、高效地表达DHAV-1VP3-3VP1蛋白。Western blot检测结果表明,表达的重组蛋白与DHAV-1和DHAV-3阳性血清均能发生特异性反应。确定间接ELISA方法的抗原最佳包被浓度为1.0μg/孔,血清最佳稀释度为1∶200,临界值为OD6 50值≥0.38,建立的间接ELISA方法具有较好的敏感性、特异性和重复性。该方法与中和试验分别检测DHAV-3阳性血清,两种方法的符合率各为96.3%和96.7%;初步临床应用结果表明该方法可用于雏鸭母源抗体和免疫后抗体的消长变化的检测。【结论】以大肠杆菌表达的DHAV-1VP3-3VP1重组蛋白建立的间接ELISA方法可用于DHAV-1和DHAV-3抗体的检测。  相似文献   

7.
根据GenBank中人源大肠杆菌pilA基因序列,用OLIGO6.0设计PCR引物,从鸭源致病性大肠杆菌GH1.2中扩增到pilA基因并将其克隆至pMD18-T载体,经PCR、酶切和DNA测序鉴定后,将鸭源致病性大肠杆菌pilA基因正向插入原核表达载体pET-32a( )的BamHⅠ和HindⅢ位点间,成功构建了重组表达质粒pET-32a-pilA。重组表达质粒pET-32a-pilA转化表达宿主菌BL21(DE3),用IPTG诱导,表达出了大小约为36kD的pilA重组蛋白。表达产物用镍柱亲和层析纯化,与等量弗氏佐剂混合制备pilA重组蛋白疫苗,分别在1日龄、8日龄时两次对雏鸭进行免疫,二免后2周测定鸭血清中的ELISA抗体效价,并以109PFU同源菌株GH1.2攻毒,根据攻毒后鸭的死亡率、E.coli分离率和各组织器官的病变等级来判定pilA重组蛋白的免疫保护效果。结果pilA重组蛋白免疫鸭的血清中ELISA抗体效价为1∶12800,全菌灭活苗免疫组的血清ELISA抗体效价为1∶200;同源菌株攻毒后,pilA重组蛋白免疫保护组鸭的死亡率、E.coli分离率和各组织器官的病变程度均比攻毒对照组下降且差异显著或极显著,与全菌灭活苗免组比较差异不显著。表明pilA重组蛋白对同源菌株GH1.2的感染具有一定的保护效果。  相似文献   

8.
虎源猫瘟热病毒VP2蛋白基因在毕赤酵母中的表达   总被引:1,自引:0,他引:1  
克隆了虎源猫瘟热病毒VP 2蛋白基因并首次在Pichia pastoris酵母中进行了分泌表达。用特异性引物从虎源FPV中扩增出VP 2基因,将其克隆到pGEM-T载体中,得到重组质粒pTVP 2进行测序。用EcoR I和NotI双酶切pTVP 2,回收目的基因VP 2片段将其定向克隆到pPICZαA中,构建出重组质粒pPICZαAVP 2。将pPICZαAVP 2用SacI内切酶线性化后,电转化毕赤酵母细胞GS115,PCR法筛选阳性重组酵母,并用1%甲醇诱导表达。结果在重组酵母菌培养物上清中经SDS-PAGE检测到相对分子量约为32 kD的重组蛋白,W estern-b lotting证实该重组蛋白可以与FPV多克隆抗体发生特异性血清学反应,表明重组VP 2蛋白具有正确的空间构象,有望作为虎FPV感染的诊断和免疫预防用抗原。  相似文献   

9.
根据GenBank已发表的猪轮状病毒vp4基因保守序列,设计一对引物扩增猪轮状病毒地方株JL94株vp4全基因;将扩增产物与载体pMD-18T连接进行序列测定并将测序结果同国外分离株进行序列比较。用限制性内切酶BamHI和SalI将vp4基因从pMD-18T-vp4切下;同样用BamHI和SalI双酶切表达载体pGEX-6P-1;将这2个双酶切产物连接并转化,通过酶切鉴定和PCR鉴定证明完成了vp4原核表达载体的构建。测序结果表明:vp4全基因长2362bp,JL94株同国外分离株BEN307株、Gottfried株vp4全基因片段核苷酸同源性分别为93.44%和69.43%;氨基酸同源性分别为96.06%和71.88%。说明JL94株同BEN-307株属同一VP4血清型,而同Gottfried株属于不同血清型。重组原核表达载体pGEX-6P1-vp4的构建为表达VP4蛋白,研制诊断性抗原和病毒重组活载体疫苗奠定了基础。  相似文献   

10.
克隆表达钩端螺旋体表层膜蛋白新基因Lslp并分析表达产物的免疫原性。根据前期研究得到的致病钩体新基因Lslp(GenBankAF32 5 80 7)的序列设计引物 ,在 6株致病钩体中扩增Lslp基因并测序。以BamHⅠ酶切Lslp和pGEX 1 λT ,构建重组质粒并用酶切和PCR鉴定 ,进一步在大肠杆菌中诱导表达 ,并进行免疫印迹分析 ;纯化表达产物免疫家兔 ,ELISA检测血清抗体滴度。结果显示Lslp在 6株致病钩体中均能扩增出相应片段 ,且序列同源性达到99 6 % ;构建高效原核表达重组质粒pGST LslP ,经IPTG诱导在大肠杆菌中可表达出 6 6kDGST融合蛋白 ,并能与全钩抗血清发生免疫印迹反应 ;将上述融合蛋白免疫新西兰大白兔产生 1 :5 1 2 0高滴度的IgG抗体。研究结果提示致病钩体膜蛋白新基因Lslp可在大肠杆菌进行高效表达 ,表达产物能被全钩抗血清识别 ,为研究钩体的致病机制和筛选保护性抗原提供了基础  相似文献   

11.
CYP1A1 and CYP1B1 are two extrahepatic enzymes that have been implicated in carcinogenesis and cancer progression. Selective inhibition of CYP1A1 and CYP1B1 by dietary constituents, notably the class of flavonoids, is a widely accepted paradigm that supports the concept of dietary chemoprevention. In parallel, recent studies have documented the ability of CYP1 enzymes to selectively metabolize dietary flavonoids to conversion products that inhibit cancer cell proliferation. In the present study we have examined the inhibition of CYP1A1 and CYP1B1-catalyzed EROD activity by 14 different flavonoids containing methoxy- and hydroxyl-group substitutions as well as the metabolism of the monomethoxylated CYP1-flavonoid inhibitor acacetin and the poly-methoxylated flavone eupatorin-5-methyl ether by recombinant CYP1A1 and CYP1B1. The most potent inhibitors of CYP1-EROD activity were the methoxylated flavones acacetin, diosmetin, eupatorin and the di-hydroxylated flavone chrysin, indicating that the 4'-OCH(3) group at the B ring and the 5,7-dihydroxy motif at the A ring play a prominent role in EROD inhibition. Potent inhibition of CYP1B1 EROD activity was also obtained for the poly-hydroxylated flavonols quercetin and myricetin. HPLC metabolism of acacetin by CYP1A1 and CYP1B1 revealed the formation of the structurally similar flavone apigenin by demethylation at the 4'-position of the B ring, whereas the flavone eupatorin-5-methyl ether was metabolized to an as yet unidentified metabolite assigned E(5)M1. Eupatorin-5-methyl ether demonstrated a submicromolar IC(50) in the CYP1-expressing cancer cell line MDA-MB 468, while it was considerably inactive in the normal cell line MCF-10A. Homology modeling in conjunction with molecular docking calculations were employed in an effort to rationalize the activity of these flavonoids based on their CYP1-binding mode. Taken together the data suggest that dietary flavonoids exhibit three distinct modes of action with regard to cancer prevention, based on their hydroxyl and methoxy decoration: (1) inhibitors of CYP1 enzymatic activity, (2) CYP1 substrates and (3) substrates and inhibitors of CYP1 enzymes.  相似文献   

12.
13.
14.
LINE-1编码蛋白L1-ORF1的原核表达纯化和多克隆抗体制备   总被引:1,自引:0,他引:1  
目的: 制备具有肿瘤组织特异性表达的L1-ORF1蛋白多克隆抗体并进行初步应用研究。方法:采取基因工程表达方法制备L1-ORF1蛋白,免疫家兔制备多克隆抗体,间接ELISA检测抗体效价,Western blot和细胞免疫荧光方法检测抗体特异性,免疫检测验证其识别肿瘤细胞内L1-ORF1蛋白的特异性。结果:制备的抗L1-ORF1蛋白多克隆抗体具有很高的敏感性与特异性,免疫学检测表明该抗体不仅能检测出正常细胞中瞬时表达的L1-ORF1蛋白,而且可检测出肿瘤细胞中天然表达的L1-ORF1蛋白。结论:制备的多克隆抗体具有较高的敏感性与特异性,为以后该抗体的进一步应用奠定了基础。  相似文献   

15.
The nucleic acid binding and unwinding properties of wild-type Escherichia coli ribosomal protein S1 have been compared to those of a mutant form and a large trypsin-resistant fragment, both reported recently [J. Mol. Biol. 127, 41-45 (1979) and J. Biol. Chem. 254, 4309-4312 (1979). The mutant (m1-S1) contains 77% and the fragment (S1-F1) 66% of the polypeptide chain length (approximately 600 amino acid residues) of protein S1. The mutant is active in protein synthesis in vitro; the fragment, although retaining one or more of the functional domains of S1, is inactive in protein synthesis. We find that m1-S1 is is almost as effective as S1 in binding to poly(rU), phage MS2 RNA and simian virus 40 (SV40) DNA, and in unfolding poly(rU) and the helical structures present in MS2 RNA and phi X174 viral DNA. S1-F1, however, binds to poly(rU) and denatured SV40 DNA, but not to MS2 RNA. It unfolds neither poly(rU), nor the residual secondary structure of MS2 RNA or phi X174 viral DNA. Thus, there appears to be a correlation between the loss in ability of S1 to unwind RNA and the loss in its ability to function in protein synthesis.  相似文献   

16.

Background

The cytochrome P450 CYP1A1 and CYP1B1 enzymes are involved in carcinogenesis via activation of pro-carcinogenic compounds to carcinogenic metabolites. CYP1A1 and CYP1B1 have shown elevated levels in human tumors as determined by qRT-PCR and immunohistochemical studies. However studies that have examined CYP1 expression by enzyme activity assays are limited.

Results

In the current study the expression of CYP1A1 and CYP1B1 was investigated in a panel of human tumors of bladder and colorectal origin by qRT-PCR and enzyme activity assays. The results demonstrated that 35% (7/20) of bladder tumors and 35% (7/20) of colon tumors overexpressed active CYP1 enzymes. CYP1B1 mRNA was overexpressed in 65% and 60% of bladder and colon tumors respectively, whereas CYP1A1 was overexpressed in 65% and 80% of bladder and colon tumors. Mean mRNA levels of CYP1B1 and CYP1A1 along with mean CYP1 activity were higher in bladder and colon tumors compared to normal tissues (p<0.05). Statistical analysis revealed CYP1 expression levels to be independent of TNM status. Moreover, incubation of tumor microsomal protein in 4 bladder and 3 colon samples with a CYP1B1 specific antibody revealed a large reduction (72.5 ± 5.5 % for bladder and 71.8 ± 7.2% for colon) in catalytic activity, indicating that the activity was mainly attributed to CYP1B1 expression.

Conclusions

The study reveals active CYP1 overexpression in human tumors and uncovers the potential use of CYP1 enzymes and mainly CYP1B1 as targets for cancer therapy.  相似文献   

17.
DEC1 and MIC-1     
Comment on: Qian Y, et al. Proc Natl Acad Sci USA 2012; 109:11300-5.  相似文献   

18.
In order to investigate the effect of the spacer in pepstatin-Sepharose on adsorption and elution of acid protease (AcP) in raw shoyu (unpasteurized soy sauce), a homologous pepstatin-aminoalkyl agarose series, (pepstatin-NH2(CH2)n-Sepharose), that varied as to the length of the hydrocarbon chains was synthesized. When raw shoyu containing many kinds of proteases was subjected to affinity chromatography on these pepstatin-Cn-Sepharoses (n = 2, 4, 6, 8, 10 and 12), all of them adsorbed AcP. With increasing length of the spacer up to 6, more and more AcP became adsorbed onto the pepstatin-Cn-Sepharose, whereas with decreasing length of the spacer, more and more AcP was eluted with 0.05 M acetate buffer (pH 3) containing 2 M urea. The AcP was purified in one step from raw shoyu and did not have any carboxypeptidase activity. Some properties of the major component of the eluted AcPs were as follows: molecular weight, 6.7 × 104, on gel filtration with TSK-G3000SW, optimum pH for activation of trypsinogen, 3.5, optimum pH for hydrolysis of hemoglobin, 2.75, and the Ki value toward pepstatin, 1.0 × 108 m.  相似文献   

19.
PCTAIRE1, also known as CDK16, is a cyclin-dependent kinase that is regulated by cyclin Y. It is a member of the serine-threonine family of kinases and its functions have primarily been implicated in cellular processes like vesicular transport, neuronal growth and development, myogenesis, spermatogenesis and cell proliferation. However, as extensive studies on PCTAIRE1 have not yet been conducted, the signaling pathways for this kinase involved in governing many cellular processes are yet to be elucidated in detail. Here, we report the association of PCTAIRE1 with important cellular proteins involved in major cell signaling pathways, especially cell proliferation. In particular, here we show that PCTAIRE1 interacts with AKT1, a key player of the PI3K signaling pathway that is responsible for promoting cell survival and proliferation. Our studies show that PCTAIRE1 is a substrate of AKT1 that gets stabilized by it. Further, we show that PCTAIRE1 also interacts with and is degraded by LKB1, a kinase that is known to suppress cellular proliferation and also regulate cellular energy metabolism. Moreover, our results show that PCTAIRE1 is also degraded by BRCA1, a well-known tumor suppressor. Together, our studies highlight the regulation of PCTAIRE1 by key players of the major cell signaling pathways involved in regulating cell proliferation, and therefore, provide crucial links that could be explored further to elucidate the mechanistic role of PCTAIRE1 in cell proliferation and tumorigenesis.  相似文献   

20.
Most strains of the insecticidal bacterium Bacillus thuringiensis have a combination of different protoxins in their parasporal crystals. Some of the combinations clearly interact synergistically, like the toxins present in B. thuringiensis subsp. israelensis. In this paper we describe a novel joint activity of toxins from different strains of B. thuringiensis. In vitro bioassays in which we used pure, trypsin-activated Cry1Ac1 proteins from B. thuringiensis subsp. kurstaki, Cyt1A1 from B. thuringiensis subsp. israelensis, and Trichoplusia ni BTI-Tn5B1-4 cells revealed contrasting susceptibility characteristics. The 50% lethal concentrations (LC50s) were estimated to be 4,967 of Cry1Ac1 per ml of medium and 11.69 ng of Cyt1A1 per ml of medium. When mixtures of these toxins in different proportions were assayed, eight different LC50s were obtained. All of these LC50s were significantly higher than the expected LC50s of the mixtures. In addition, a series of bioassays were performed with late first-instar larvae of the cabbage looper and pure Cry1Ac1 and Cyt1A1 crystals, as well as two different combinations of the two toxins. The estimated mean LC50 of Cry1Ac1 was 2.46 ng/cm2 of diet, while Cyt1A1 crystals exhibited no toxicity, even at very high concentrations. The estimated mean LC50s of Cry1Ac1 crystals were 15.69 and 19.05 ng per cm2 of diet when these crystals were mixed with 100 and 1,000 ng of Cyt1A1 crystals per cm2 of diet, respectively. These results indicate that there is clear antagonism between the two toxins both in vitro and in vivo. Other joint-action analyses corroborated these results. Although this is the second report of antagonism between B. thuringiensis toxins, our evidence is the first evidence of antagonism between toxins from different subspecies of B. thuringiensis (B. thuringiensis subsp. kurstaki and B. thuringiensis subsp. israelensis) detected both in vivo and in vitro. Some possible explanations for this relationship are discussed.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号